Evidence for the Analgesic Activity of Resveratrol in Acute Models of Nociception in Mice

• Published in: Journal of natural products (Washington, D.C.) Vol. 76; no. 1; pp. 13 - 21
• Main Authors: Bazzo, Karen O, Souto, André A, Lopes, Tiago G, Zanin, Rafael F, Gomez, Marcus V, Souza, Alessandra H, Campos, Maria M
• Format: Journal Article
• Language: English
• Published: United States American Chemical Society and American Society of Pharmacognosy 25-01-2013
• Subjects: Analgesics - administration & dosage; Analgesics - pharmacology; Animals; Behavior, Animal - drug effects; Capsaicin - administration & dosage; Capsaicin - pharmacology; Cyclooxygenase 2 - analysis; Cyclooxygenase 2 - genetics; Disease Models, Animal; Dose-Response Relationship, Drug; Glutamic Acid - administration & dosage; Glutamic Acid - pharmacology; Male; Mice; Molecular Structure; Nociception - drug effects; Pain Measurement - drug effects; Proto-Oncogene Proteins c-fos - analysis; Proto-Oncogene Proteins c-fos - genetics; Stereoisomerism; Stilbenes - chemistry; Stilbenes - pharmacology
• ISSN: 0163-3864; 1520-6025
• DOI: 10.1021/np300529x

The effects of trans-resveratrol (1) were evaluated in acute nociception models induced by capsaicin or glutamate in mice, in an attempt to further characterize its mechanism of action. The oral administration of 1 (50 and 100 mg/kg) reduced significantly the licking behavior elicited by capsaicin (1.6 μg/paw) or glutamate (10 μmol/paw). The co-administration of 1 into the mouse paw (200 μg/site) markedly prevented glutamate-induced licking, without affecting capsaicin responses. In addition, the intrathecal (it) injection of 1 (150 to 600 μg/site) greatly reduced the licking behavior caused by capsaicin, but not glutamate. Similarly, the intracerebroventricular injection of 1 (300 μg/site) caused a potent inhibition of capsaicin-induced nociception, while the glutamate responses remained unaffected. However, the co-administration of 1 (300 μg/site) reduced the biting behavior induced by spinal injection of glutamate (30 μg/site, it), leaving capsaicin (6.4 μg/site)-induced biting unaltered. Notably, the oral administration of 1 (100 mg/kg) inhibited significantly the capsaicin-induced increase of c-Fos and COX-2 labeling in the spinal cord and COX-2 expression in the cortex, but failed to affect c-Fos and COX-2 expression in the glutamate model. This study has explored the effects of 1 in both the capsaicin and glutamate models, extending current knowledge on the analgesic effects of trans-resveratrol.